Financials data is unavailable for this security.
View more
Year on year Benitec Biopharma Inc 's net income fell 7.44% from a loss of 18.21m to a larger loss of 19.56m despite relatively flat revenues.
| Gross margin | 1,542.86% |
|---|---|
| Net profit margin | -309,885.70% |
| Operating margin | -307,028.60% |
| Return on assets | -186.85% |
|---|---|
| Return on equity | -267.59% |
| Return on investment | -260.89% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Benitec Biopharma Inc fell by 1.59m. Cash Flow from Financing totalled 16.02m or 21,353.33% of revenues. In addition the company used 18.01m for operations while cash used for investing totalled 1.00k.
| Cash flow per share | -9.61 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.22 |
|---|---|
| Tangible book value per share | 4.22 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.18 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 62.73%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 59.77 |
